icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
kw0Z7uDY05zb1xy1